label,canonical,first_pmid,node_id
Adverse event,adrenal insufficiency,28988646,N000000
Adverse event,anaemia,28499583,N000001
Adverse event,anorexia,29650362,N000002
Adverse event,arterial hypertension,27751846,N000003
Adverse event,asthenia,27751846,N000004
Adverse event,atrophy,15337565,N000005
Adverse event,bladder dysfunction,18052409,N000006
Adverse event,bleeding,39582122,N000007
Adverse event,blood los during surgery,22340347,N000008
Adverse event,bone growth abnormalitie,15337565,N000009
Adverse event,bone growth arrest,18052409,N000010
Adverse event,chest pain,30477937,N000011
Adverse event,decreased lymphocyte count,28988646,N000012
Adverse event,dehydration,31160249,N000013
Adverse event,diarrhoea,31160249,N000014
Adverse event,edema,15337565,N000015
Adverse event,fatigue,30477937,N000016
Adverse event,febrile neutropenia,18052409,N000017
Adverse event,fibrosi,15337565,N000018
Adverse event,grade 3 adverse event,31160249,N000019
Adverse event,grade 4 adverse event,31786124,N000020
Adverse event,hand and foot skin reaction,27751846,N000021
Adverse event,hand foot skin reaction,30477937,N000022
Adverse event,hemoptysi,33035459,N000023
Adverse event,hepatopathy,18052409,N000024
Adverse event,hypertension,31160249,N000025
Adverse event,hypophosphataemia,30477937,N000026
Adverse event,immune related sae,28988646,N000027
Adverse event,impairment of mobility and extremity function,15337565,N000028
Adverse event,increased aspartate aminotransferase,31331701,N000029
Adverse event,increased concentration of alanine aminotransferase,31331701,N000030
Adverse event,induction of second malignant neoplasm,18052409,N000031
Adverse event,infertility,18052409,N000032
Adverse event,intracranial hemorrhage,31160249,N000033
Adverse event,intraoperative injury,22340347,N000034
Adverse event,liver failure,27751846,N000035
Adverse event,moderate to severe limitation of movement,15337565,N000036
Adverse event,muscle atrophy,18052409,N000037
Adverse event,muscle spasm,29650362,N000038
Adverse event,myelosuppression,18052409,N000039
Adverse event,nausea,29650362,N000040
Adverse event,nephriti,28988646,N000041
Adverse event,neutropenia,28499583,N000042
Adverse event,no perioperative death,22340347,N000043
Adverse event,no treatment related death,30477937,N000044
Adverse event,otiti,16601376,N000045
Adverse event,pain requiring iv medication,39582122,N000046
Adverse event,peripheral nerve injury,15337565,N000047
Adverse event,pneumoniti,28988646,N000048
Adverse event,postoperative joint stiffnes,38153106,N000049
Adverse event,postoperative numbnes at the surgical site,38876200,N000050
Adverse event,prolonged activated partial thromboplastin time,28988646,N000051
Adverse event,proteinuria,31160249,N000052
Adverse event,radial nerve palsy,15337565,N000053
Adverse event,radiation induced myelopathy,16601376,N000054
Adverse event,second malignant neoplasm,18052409,N000055
Adverse event,seizure,33035459,N000056
Adverse event,skin burn,39582122,N000057
Adverse event,thrombocytopenia,28499583,N000058
Adverse event,transient esophagiti,16601376,N000059
Adverse event,treatment related death,31160249,N000060
Adverse event,vascular injury,38153106,N000061
Adverse event,vomiting,31160249,N000062
Adverse event,weight los,33035459,N000063
Adverse event,wound complication that required surgery,31786124,N000064
Anatomical Site,abdomen,20829680,N000065
Anatomical Site,abdominal,35673808,N000066
Anatomical Site,abdominal wall,17890911,N000067
Anatomical Site,adductor muscle,19363438,N000068
Anatomical Site,adrenal gland,17998131,N000069
Anatomical Site,aorta,16096408,N000070
Anatomical Site,aortic arch,14670013,N000071
Anatomical Site,ascending aorta,14670013,N000072
Anatomical Site,back,17890911,N000073
Anatomical Site,base of the skull,16601376,N000074
Anatomical Site,bladder neck,37879305,N000075
Anatomical Site,bone,26905128,N000076
Anatomical Site,buccal fat pad,22134298,N000077
Anatomical Site,buccal space,22134298,N000078
Anatomical Site,central nervou system,21938461,N000079
Anatomical Site,cerebellar pontine angle,21938461,N000080
Anatomical Site,cerebellopontine angle,21938461,N000081
Anatomical Site,cranial nerve,20399579,N000082
Anatomical Site,deep groin,14508393,N000083
Anatomical Site,deep soft tissue,23327728,N000084
Anatomical Site,deep soft tissue of thigh,19718788,N000085
Anatomical Site,duodenum,24279301,N000086
Anatomical Site,ear,20123452,N000087
Anatomical Site,extremitie,14669292,N000088
Anatomical Site,extremity,18820664,N000089
Anatomical Site,eyelid,20123452,N000090
Anatomical Site,face,20123452,N000091
Anatomical Site,facial buccal branche,22134298,N000092
Anatomical Site,femoral arterie,16096408,N000093
Anatomical Site,gastrocnemiu,19363438,N000094
Anatomical Site,gastrointestinal tract,29661713,N000095
Anatomical Site,genital,18551749,N000096
Anatomical Site,groin muscle,19363438,N000097
Anatomical Site,head,20829680,N000098
Anatomical Site,heart,39658531,N000099
Anatomical Site,inguinal area,17890911,N000100
Anatomical Site,intraperitoneal,24279301,N000101
Anatomical Site,intraperitoneal location,24279301,N000102
Anatomical Site,jejunum,24279301,N000103
Anatomical Site,kidney,27428733,N000104
Anatomical Site,knee,38153106,N000105
Anatomical Site,large nerve root and bundle,38954182,N000106
Anatomical Site,large systemic vein,16096408,N000107
Anatomical Site,left external iliac,16096408,N000108
Anatomical Site,left lower leg,20123452,N000109
Anatomical Site,left side of the abdomen,36254545,N000110
Anatomical Site,left upper arm,23648456,N000111
Anatomical Site,leg,14508393,N000112
Anatomical Site,lip,15509490,N000113
Anatomical Site,liver,36483242,N000114
Anatomical Site,lower arm,20123452,N000115
Anatomical Site,lower extremitie,19363438,N000116
Anatomical Site,lower extremity,35901432,N000117
Anatomical Site,lower limb,30421387,N000118
Anatomical Site,lung,14669292,N000119
Anatomical Site,lymph node,29529647,N000120
Anatomical Site,masseter muscle,22134298,N000121
Anatomical Site,masticator space,12916461,N000122
Anatomical Site,mediastinum,20829680,N000123
Anatomical Site,mentali,19363438,N000124
Anatomical Site,mesentery,24279301,N000125
Anatomical Site,meso hypogastrium,24279301,N000126
Anatomical Site,mobile spine,21184634,N000127
Anatomical Site,myometrium,35673808,N000128
Anatomical Site,neck,19363438,N000129
Anatomical Site,non extremitie,34502329,N000130
Anatomical Site,nose,20123452,N000131
Anatomical Site,omentum,19718788,N000132
Anatomical Site,orbit,21056898,N000133
Anatomical Site,paranasal sinuse,12916461,N000134
Anatomical Site,parotid duct,22134298,N000135
Anatomical Site,parotid gland,22002440,N000136
Anatomical Site,pelvi,21184634,N000137
Anatomical Site,pelvic,35673808,N000138
Anatomical Site,posterior mediastinum,25475695,N000139
Anatomical Site,posterior one third of the left fourth rib,17998131,N000140
Anatomical Site,prostate,35125107,N000141
Anatomical Site,proximal extremitie,36254545,N000142
Anatomical Site,renal,21836481,N000143
Anatomical Site,retroperitoneal,36438917,N000144
Anatomical Site,retroperitoneum,18820664,N000145
Anatomical Site,retrorectal space,22340347,N000146
Anatomical Site,right cheek,22134298,N000147
Anatomical Site,sacrum,21184634,N000148
Anatomical Site,scalp,12916461,N000149
Anatomical Site,sciatic nerve,21460792,N000150
Anatomical Site,shoulder,17890911,N000151
Anatomical Site,skin of the scalp,20123452,N000152
Anatomical Site,skin thyroid,17998131,N000153
Anatomical Site,smooth muscle of the uteru,35673808,N000154
Anatomical Site,soft tissue,26905128,N000155
Anatomical Site,spinal,27834629,N000156
Anatomical Site,spinal cord,20399579,N000157
Anatomical Site,sternocleidomastoid muscle,19363438,N000158
Anatomical Site,subcutaneou area,34502329,N000159
Anatomical Site,submandibular region,22134298,N000160
Anatomical Site,t4 spine,17998131,N000161
Anatomical Site,temple,20123452,N000162
Anatomical Site,thigh,17890911,N000163
Anatomical Site,truncal,39230901,N000164
Anatomical Site,trunk,19363438,N000165
Anatomical Site,trunk wall,14669292,N000166
Anatomical Site,tunica intima,16096408,N000167
Anatomical Site,upper and lower extremitie,31692830,N000168
Anatomical Site,upper arm,17890911,N000169
Anatomical Site,upper cervical region,16601376,N000170
Anatomical Site,upper extremitie,20829680,N000171
Anatomical Site,upper extremity,19363438,N000172
Anatomical Site,upper thigh,14508393,N000173
Anatomical Site,urinary bladder,18580491,N000174
Anatomical Site,uterine,32075391,N000175
Anatomical Site,uteru,30447212,N000176
Anatomical Site,vaginal,35673808,N000177
Anatomical Site,vastu laterali,19363438,N000178
Anatomical Site,visceral aorta,14670013,N000179
Biology Feature,4 mitose 10hpf,34502329,N000180
Biology Feature,a thin layer of viable tumor cell overlying a large thrombu,16096408,N000181
Biology Feature,absence of sma,20123452,N000182
Biology Feature,abundant pale eosinophilic cytoplasm,23327728,N000183
Biology Feature,activation of telomere maintenance pathway,27562490,N000184
Biology Feature,adipocyte,21056898,N000185
Biology Feature,albumin,25370967,N000186
Biology Feature,amplification of the 12q13 15 region,18820664,N000187
Biology Feature,apoplectic change,26715170,N000188
Biology Feature,apoptosi,36729612,N000189
Biology Feature,bcor overexpression,27428733,N000190
Biology Feature,bizarre nuclei,26715170,N000191
Biology Feature,blastemal predominant subtype,15175957,N000192
Biology Feature,cd123 positive plasmacytic dendritic cell,19363438,N000193
Biology Feature,cd163 positive macrophage,19363438,N000194
Biology Feature,cd20 positive b cell,19363438,N000195
Biology Feature,cd3 cd4 positive lymphocyte,19363438,N000196
Biology Feature,cell pleomorphism,35673808,N000197
Biology Feature,cell size area cm2,32124739,N000198
Biology Feature,cellular area with a partial hemangiopericytoma pattern,21938461,N000199
Biology Feature,classical hematoxylin eosin he staining,35673808,N000200
Biology Feature,coexpression of keratin and endothelial marker,28009608,N000201
Biology Feature,complex chromosomal rearrangement,12661001,N000202
Biology Feature,cord strand and solid aggregate of round oval and polygonal cell,23327728,N000203
Biology Feature,cystic degeneration,24279301,N000204
Biology Feature,cytogenetic finding,12916461,N000205
Biology Feature,cytologic atypia,21056898,N000206
Biology Feature,dedifferentiation,34502329,N000207
Biology Feature,dense band of collagen appeared in cros section a minute nodule that separated individual tumor cell,21938461,N000208
Biology Feature,diffuse anaplasia,15175957,N000209
Biology Feature,diffusely infiltrating growth,17890911,N000210
Biology Feature,doubly indented spindle cell,21045379,N000211
Biology Feature,embedded in a fibromyxoid or sclerotic stroma,23327728,N000212
Biology Feature,epithelial and stromal predominant,15175957,N000213
Biology Feature,epithelioid morphology,17163160,N000214
Biology Feature,fibrolipoma,22134298,N000215
Biology Feature,fibrosi,19363438,N000216
Biology Feature,focal anaplasia,15175957,N000217
Biology Feature,focal fibrosarcomatou and focal giant cell fibroblastoma like change,17890911,N000218
Biology Feature,focal myxoid area,34502329,N000219
Biology Feature,focal neurogenic,19363438,N000220
Biology Feature,focal weak fosb staining,28009608,N000221
Biology Feature,foci of lymphovascular invasion,35125107,N000222
Biology Feature,ghr expression,18225592,N000223
Biology Feature,h3k27me3 los,38178234,N000224
Biology Feature,have higher pd l1 expression,34925348,N000225
Biology Feature,hemoglobin,25370967,N000226
Biology Feature,high expression of cancer testi antigen cta,34925348,N000227
Biology Feature,histone acetylation and nuclear heparanase level,34857011,N000228
Biology Feature,hotspot area easier to locate in whole section,36613891,N000229
Biology Feature,hypercellularity,34502329,N000230
Biology Feature,hypocellular area,17890911,N000231
Biology Feature,immunohistochemical feature,18820664,N000232
Biology Feature,inconspicuou nucleoli,23327728,N000233
Biology Feature,increased mitotic activity,21056898,N000234
Biology Feature,infiltration,26715170,N000235
Biology Feature,infiltrative growth pattern,20123452,N000236
Biology Feature,inflammation,19363438,N000237
Biology Feature,isolated patulou vessel,22002440,N000238
Biology Feature,keloid like to wiry collagen wa present between the neoplastic cell,22002440,N000239
Biology Feature,lack hif 1alpha expression,20123452,N000240
Biology Feature,large cell with an epethelioid morphology,17998131,N000241
Biology Feature,low level amplified sequence from 17q22 qter and 22q10 q131 or t1722,12661001,N000242
Biology Feature,lymphoplasmacytic infiltrate,26715170,N000243
Biology Feature,lymphovascular invasion,26715170,N000244
Biology Feature,major histocompatibility complex 1 and weak igg4 were focally positive,19363438,N000245
Biology Feature,matrix rich in proteoglycan and glycosaminoglycan,35673808,N000246
Biology Feature,mdm2 and cdk4 staining,18820664,N000247
Biology Feature,mild to moderate lymphocytic inflammatory,20123452,N000248
Biology Feature,mitose,22002440,N000249
Biology Feature,mitotic activity,26715170,N000250
Biology Feature,mitotic rate,17890911,N000251
Biology Feature,morphologic pattern,24279301,N000252
Biology Feature,multifocal geographic necrose,35125107,N000253
Biology Feature,multifocal presentation,28009608,N000254
Biology Feature,myxoid area,18820664,N000255
Biology Feature,myxoid change,26715170,N000256
Biology Feature,myxoid mas,24279301,N000257
Biology Feature,myxoid stromal change,17890911,N000258
Biology Feature,necrosi,34502329,N000259
Biology Feature,necrosi wa absent,22002440,N000260
Biology Feature,neutrophil to lymphocyte ratio,25370967,N000261
Biology Feature,nuclear pleomorphism,35673808,N000262
Biology Feature,nuclear staining,14508393,N000263
Biology Feature,numerou blood vessel with slightly fibrosed vessel wall,17890911,N000264
Biology Feature,oval to spindle shaped cell arranged in sheet and fascicle or herringbone like pattern within a small amount of edematou to myxoid vascularized stroma,35125107,N000265
Biology Feature,overlapping feature with soft tissue giant cell fibroblastoma,21056898,N000266
Biology Feature,p53 and p16 overexpression,19718788,N000267
Biology Feature,papillary endothelial hyperplasia like foci,20123452,N000268
Biology Feature,plump spindled and epithelioid cell,28009608,N000269
Biology Feature,polyploidy,29197031,N000270
Biology Feature,poorly differentiated epithelioid and pleomorphic malignant neoplasm,16096408,N000271
Biology Feature,predominant myxoid component,35673808,N000272
Biology Feature,presence of large polygonal epithelioid malignant cell with marked cellular atypia and pleomorphism,17998131,N000273
Biology Feature,presence of node,32124739,N000274
Biology Feature,presence of villou growth,32124739,N000275
Biology Feature,proliferation,36729612,N000276
Biology Feature,prominent eosinophil,19363438,N000277
Biology Feature,prominent mitotic figure,35125107,N000278
Biology Feature,rare mitosi on high power field,35673808,N000279
Biology Feature,rarely it may contain melanin pigment,26715170,N000280
Biology Feature,reactivity for at least 3 of 5 immunohistochemistry ihc marker,21412072,N000281
Biology Feature,rhabdoid morphology,35125107,N000282
Biology Feature,round cell tumor with pathology consistent with ewing sarcoma,28141799,N000283
Biology Feature,s 100 protein positivity,21045379,N000284
Biology Feature,scattered enlarged tumor cell,17890911,N000285
Biology Feature,severity of hemosiderosi,32124739,N000286
Biology Feature,siglec 15 and pd l1 expression were evaluated using immunohistochemistry,36438917,N000287
Biology Feature,skeletal muscle fiber with vacuolar change,19363438,N000288
Biology Feature,smooth muscle component,25475695,N000289
Biology Feature,solid architecture,20123452,N000290
Biology Feature,spindle cell lipoma,22134298,N000291
Biology Feature,spindle to oval cell were disposed in wavy fascicle between prominent eosinophilic band of collagen,21938461,N000292
Biology Feature,spindled cell showed tapering cytoplasm with monotonou round to oval nuclei with coarse nuclear chromatin distribution,22002440,N000293
Biology Feature,stromal collagen,21056898,N000294
Biology Feature,stromal intramembranou ossification,21056898,N000295
Biology Feature,stromal myxoid change,21056898,N000296
Biology Feature,strong and diffuse nuclear bcor immunoreactivity,27428733,N000297
Biology Feature,strong diffuse cytoplasmic staining for muc4,22982887,N000298
Biology Feature,the distinctive histopathologic appearance of the primary luminal lesion wa lost whenever tumor invaded outside the vessel wall,16096408,N000299
Biology Feature,the number of multinucleated giant cell,32124739,N000300
Biology Feature,the sum of longest tumor diameter sld visualized by cros sectional imaging correlated significantly with paired tumor fraction in plasma,34464388,N000301
Biology Feature,tumor cell necrosi,26715170,N000302
Biology Feature,tumor showed focally entrapped normal salivary gland acini and duct at the edge,22002440,N000303
Biology Feature,tumor were cellular,22002440,N000304
Biology Feature,tumor were described a well circumscribed to encapsulated firm homogenou white to tan masse,22002440,N000305
Biology Feature,type of predominant cellular proliferate,32124739,N000306
Biology Feature,uncertain behavior to low grade malignant,21056898,N000307
Biology Feature,unusual multivacuolated adipocytic cell,21056898,N000308
Biology Feature,variable hemorrhage,24279301,N000309
Biology Feature,variable mitotic activity,35673808,N000310
Biology Feature,variable myopathic,19363438,N000311
Biology Feature,vascular crow feet pattern,18820664,N000312
Biology Feature,vesicular nuclei,23327728,N000313
Drug,amg 900,29197031,N000314
Drug,anthracycline,27751846,N000315
Drug,anthracycline plu ifosfamide,38954182,N000316
Drug,antiangiogenic,34925348,N000317
Drug,azd1152 hqpa,29197031,N000318
Drug,bendamustine,18572972,N000319
Drug,bevacizumab,18572972,N000320
Drug,cediranib,31160249,N000321
Drug,cisplatin,35125107,N000322
Drug,dacarbazine,28499583,N000323
Drug,dna minor groove binder,18572972,N000324
Drug,dna topoisomerase i inhibitor,18572972,N000325
Drug,docetaxel,28499583,N000326
Drug,doxorubicin,31786124,N000327
Drug,efavirenz,36264536,N000328
Drug,epirubicin,28499583,N000329
Drug,esomeprazole,36264536,N000330
Drug,etoposide,35125107,N000331
Drug,fk228,34857011,N000332
Drug,fluconazole,36264536,N000333
Drug,gemcitabine,28499583,N000334
Drug,hdac inhibitor,34857011,N000335
Drug,ifosfamide,28499583,N000336
Drug,imatinib,18572972,N000337
Drug,imatinib mesilat,36254545,N000338
Drug,imatinib mesylate,17163160,N000339
Drug,intratumoral talimogene laherpavec,34925348,N000340
Drug,intravenou etoposide,28499583,N000341
Drug,intravenou ifosfamide,28499583,N000342
Drug,irinotecan,18052409,N000343
Drug,itraconazole,36264536,N000344
Drug,mk 5108,29197031,N000345
Drug,multi tyrosine kinase inhibitor,18572972,N000346
Drug,olaratumab,32075391,N000347
Drug,pazopanib,27751846,N000348
Drug,pembrolizumab,28988646,N000349
Drug,pexidartinib,36264536,N000350
Drug,probenecid,36264536,N000351
Drug,regorafenib,30477937,N000352
Drug,rifampin,36264536,N000353
Drug,saha,34857011,N000354
Drug,single agent doxorubicin,31331295,N000355
Drug,sst0001 roneparstat,34857011,N000356
Drug,talazoparib,36729612,N000357
Drug,taxane,18572972,N000358
Drug,tazemetostat,29650362,N000359
Drug,temozolomide,18572972,N000360
Drug,thrombospondin agonist abt 510,18572972,N000361
Drug,topotecan,18052409,N000362
Drug,trabectedin,28499583,N000363
Drug,trametinib,34857011,N000364
Drug,trofosfamide,18572972,N000365
Drug,tyrosine kinase braf or mek inhibitor,30646278,N000366
Drug,tyrosine kinase inhibitor,38014853,N000367
Drug response outcome,cytoprotective,34857011,N000368
Drug response outcome,improving progression free survival,27751846,N000369
Drug response outcome,modest improvement in pain,36001000,N000370
Drug response outcome,no treatment related death,29650362,N000371
Drug response outcome,objective response,33035459,N000372
Drug response outcome,reduction in tumor size,36001000,N000373
Drug response outcome,yield an impressive 35% orr when associated to pembrolizumab,34925348,N000374
Evaluation Result,exces over blis score ch2879 59% lower 95% ci 52% jj012 18% lower 95% ci 8% and sw1353 55% lower 95% ci 25% of thi combination treatment,36729612,N000375
Evaluation Result,for the evaluable population wa 83% iqr 265 to 59 with cediranib versu 134% iqr 11 to 213 with placebo one sided p00010,31160249,N000376
Follow-up Plan,clinical follow up of patient with dfsp after tumor excision should be performed every six month for the first five year,36254545,N000377
Follow-up Plan,close postoperative follow up i,20399579,N000378
Follow-up Plan,regular yearly or more frequent follow up,17338203,N000379
Gene,ahsg,36438917,N000380
Gene,akt,38954182,N000381
Gene,alk,17163160,N000382
Gene,ambp,36438917,N000383
Gene,apoa1,36438917,N000384
Gene,arid1a,35125107,N000385
Gene,atf1,17163160,N000386
Gene,aurora kinase a,29197031,N000387
Gene,aurora kinase b,29197031,N000388
Gene,bcl 2,22002440,N000389
Gene,bcl2,32948135,N000390
Gene,bcl6,32948135,N000391
Gene,bcor,27428733,N000392
Gene,camta1,26811225,N000393
Gene,ccnb3,27428733,N000394
Gene,cd34,17890911,N000395
Gene,cd99,22002440,N000396
Gene,cdk4,18820664,N000397
Gene,cdkn2a,37585199,N000398
Gene,cdkn2a b,39563528,N000399
Gene,cebpb,39658531,N000400
Gene,cep290,38014853,N000401
Gene,chop,17163160,N000402
Gene,chop translocation at 12q131 q132,25475695,N000403
Gene,classic ra,34530870,N000404
Gene,cltc,38014853,N000405
Gene,col1a1,17890911,N000406
Gene,creb3l1,22982887,N000407
Gene,cyclin d1,32948135,N000408
Gene,egfr,38014853,N000409
Gene,erbb4,31291965,N000410
Gene,etv6,17163160,N000411
Gene,ew,17163160,N000412
Gene,ewsr1,28141799,N000413
Gene,ezh2,29650362,N000414
Gene,f2,36438917,N000415
Gene,fli1,17163160,N000416
Gene,fm like tyrosine kinase 3,36264536,N000417
Gene,fosb,28009608,N000418
Gene,foxp2,38014853,N000419
Gene,fu,17163160,N000420
Gene,h ra,34530870,N000421
Gene,hter,36613891,N000422
Gene,ick,38014853,N000423
Gene,ini1,29650362,N000424
Gene,k ra,34530870,N000425
Gene,kdr,38014853,N000426
Gene,ki67,32948135,N000427
Gene,kit,17163160,N000428
Gene,kit proto oncogene receptor tyrosine kinase,36264536,N000429
Gene,lmna,38014853,N000430
Gene,m ra,34530870,N000431
Gene,maml3,27428733,N000432
Gene,mapk,38954182,N000433
Gene,mdm2,39563528,N000434
Gene,mdm2 at 12q13 15,25475695,N000435
Gene,met,38014853,N000436
Gene,mtor,38954182,N000437
Gene,myc,39658531,N000438
Gene,n ra,34530870,N000439
Gene,nab2,30233017,N000440
Gene,nf1,23218951,N000441
Gene,nf2,17163160,N000442
Gene,nr4a3,31331701,N000443
Gene,nrg1beta,31291965,N000444
Gene,ntrk,17163160,N000445
Gene,ntrk1,38014853,N000446
Gene,ntrk3,38014853,N000447
Gene,nutm2b,27428733,N000448
Gene,p21,32948135,N000449
Gene,p53,38954182,N000450
Gene,pd l1,36438917,N000451
Gene,pdgfb,17890911,N000452
Gene,pdgfr,32075391,N000453
Gene,pdgfra,17163160,N000454
Gene,pikc3,39563528,N000455
Gene,prc2,38954182,N000456
Gene,pten,39563528,N000457
Gene,r ra,34530870,N000458
Gene,r ras2,34530870,N000459
Gene,ra,38954182,N000460
Gene,rf,21938461,N000461
Gene,s 100,21938461,N000462
Gene,serpinc1,36438917,N000463
Gene,serpine1,28009608,N000464
Gene,siglec 15,36438917,N000465
Gene,smarca2,34464388,N000466
Gene,smarca4,29650362,N000467
Gene,smarcb1,33035459,N000468
Gene,sox2,29773426,N000469
Gene,ss18,29773426,N000470
Gene,ssx,17163160,N000471
Gene,stat6,30233017,N000472
Gene,strn3,38014853,N000473
Gene,suz12,34464388,N000474
Gene,syt,17163160,N000475
Gene,tal1,39658531,N000476
Gene,tert,27562490,N000477
Gene,tp53,39563528,N000478
Gene,tpm3,17163160,N000479
Gene,trp53,31291965,N000480
Gene,vimentin,21938461,N000481
Gene,vwc2,38014853,N000482
Gene,wwtr1,26811225,N000483
Gene,ywhae,27428733,N000484
Gene Fusion,alk tpm3,17163160,N000485
Gene Fusion,bcor ccnb3,27428733,N000486
Gene Fusion,bcor maml3,27428733,N000487
Gene Fusion,cep290 met,38014853,N000488
Gene Fusion,cltc alk,38014853,N000489
Gene Fusion,col1a1 pdgfb,12661001,N000490
Gene Fusion,col1a1 pdgfb fusion gene,17890911,N000491
Gene Fusion,etv6 ntrk,17163160,N000492
Gene Fusion,ew atf1,17163160,N000493
Gene Fusion,ew chop,18820664,N000494
Gene Fusion,ew fli1,17163160,N000495
Gene Fusion,ewsr1 rearrangement,28141799,N000496
Gene Fusion,fosb gene fusion,28009608,N000497
Gene Fusion,foxp2 met,38014853,N000498
Gene Fusion,fu chop,17163160,N000499
Gene Fusion,ick kdr,38014853,N000500
Gene Fusion,lmna ntrk1,38014853,N000501
Gene Fusion,nab2 stat6,34502329,N000502
Gene Fusion,nab2ex3 stat6ex19,28869107,N000503
Gene Fusion,nab2ex4 stat6ex2,28869107,N000504
Gene Fusion,nab2ex4 stat6ex4,28869107,N000505
Gene Fusion,nab2ex6 sat6ex16,28869107,N000506
Gene Fusion,nab2ex6 stat6ex17,28869107,N000507
Gene Fusion,nab2ex6 stat6ex3,28869107,N000508
Gene Fusion,nab2ex7 stat6ex2,28869107,N000509
Gene Fusion,nr4a3 translocated,31331701,N000510
Gene Fusion,serpine1 fosb fusion,28009608,N000511
Gene Fusion,ss18 ssx fusion oncogene,34857011,N000512
Gene Fusion,ss18 ssx gene fusion,29773426,N000513
Gene Fusion,strn3 ntrk3,38014853,N000514
Gene Fusion,syt ssx,17163160,N000515
Gene Fusion,vwc2 egfr,38014853,N000516
Gene Fusion,wwtr1 camta1,26811225,N000517
Gene Fusion,ywhae nutm2b,27428733,N000518
Histological Subtype,alveolar rhabdomyosarcoma,37477762,N000519
Histological Subtype,biphasic synovial sarcoma,22982887,N000520
Histological Subtype,ddlp,30421387,N000521
Histological Subtype,de differentiated liposarcoma,25475695,N000522
Histological Subtype,dedifferentiated chondrosarcoma,15111298,N000523
Histological Subtype,dedifferentiated liposarcoma,33112583,N000524
Histological Subtype,embryonal rhabdomyosarcoma,37477762,N000525
Histological Subtype,epithelioid angiosarcoma,22982887,N000526
Histological Subtype,epithelioid gastrointestinal stromal tumor,22982887,N000527
Histological Subtype,epithelioid liposarcoma,17175794,N000528
Histological Subtype,epithelioid malignant peripheral nerve sheath tumor,23648456,N000529
Histological Subtype,fibroma like epithelioid sarcoma,20829680,N000530
Histological Subtype,fibrosarcomatou dermatofibrosarcoma protuberan,37477762,N000531
Histological Subtype,fibrosarcomatou myofibroblastic and granular cell dfsp,17890911,N000532
Histological Subtype,high grade myxoid liposarcoma,28499583,N000533
Histological Subtype,hpc phenotype,30233017,N000534
Histological Subtype,intraperitoneal dedifferentiated liposarcoma,24279301,N000535
Histological Subtype,lipoleiomyosarcoma,17175794,N000536
Histological Subtype,malignant sft,28869107,N000537
Histological Subtype,mlp,30421387,N000538
Histological Subtype,myxoid leiomyosarcoma,35673808,N000539
Histological Subtype,myxoid liposarcoma,28499583,N000540
Histological Subtype,myxoid or round cell liposarcoma,26970672,N000541
Histological Subtype,myxoid round cell liposarcoma,29529647,N000542
Histological Subtype,pigmented dermatofibrosarcoma protuberan,17175794,N000543
Histological Subtype,pleomorphic liposarcoma,25475695,N000544
Histological Subtype,pleomorphic rhabdomyosarcoma,37477762,N000545
Histological Subtype,plp,30421387,N000546
Histological Subtype,poorly differentiated synovial sarcoma,29661713,N000547
Histological Subtype,proximal type epithelioid sarcoma,17175794,N000548
Histological Subtype,round cell liposarcoma,25475695,N000549
Histological Subtype,sclerosing rhabdomyosarcoma,29661713,N000550
Histological Subtype,sft phenotype,30233017,N000551
Histological Subtype,spindle cell angiosarcoma,28009608,N000552
Histological Subtype,spindle cell mpnst,23648456,N000553
Histological Subtype,spindle cell rhabdomyosarcoma,38876200,N000554
Histological Subtype,wdlp,30421387,N000555
Histological Subtype,well differentiated liposarcoma,24279301,N000556
Imaging Feature,absence of fibrotic component,30560359,N000557
Imaging Feature,absence of tail sign,30560359,N000558
Imaging Feature,adc cutoff value of 09 10,40273759,N000559
Imaging Feature,asymptomatic recurrence found during regular mri,38153106,N000560
Imaging Feature,biphasic pattern,33112583,N000561
Imaging Feature,central area of necrosi,30560359,N000562
Imaging Feature,centrally located palpable nodule measuring between 3 and 5 mm,36254545,N000563
Imaging Feature,deep location,30560359,N000564
Imaging Feature,dw signal intensity,40273759,N000565
Imaging Feature,enlarged pelvic lymph node,40273759,N000566
Imaging Feature,extent of disease,31786124,N000567
Imaging Feature,heterogeneou density mas,24279301,N000568
Imaging Feature,high signal intensitie on t1 weighted imaging,30560359,N000569
Imaging Feature,histopathological mimic,18820664,N000570
Imaging Feature,ill defined plaque measuring 10 cm,36254545,N000571
Imaging Feature,infiltrative growth pattern,30560359,N000572
Imaging Feature,infiltrative irregular tumor margin,35673808,N000573
Imaging Feature,irregular tumor margin,40273759,N000574
Imaging Feature,kidney mas,26337721,N000575
Imaging Feature,large ill defined prostatic mas lesion with circumferential extension into the rectal wall,35125107,N000576
Imaging Feature,large lobulated masse,25475695,N000577
Imaging Feature,largely necrotic,16096408,N000578
Imaging Feature,mas response,16601376,N000579
Imaging Feature,mean tumor size wa 45,22002440,N000580
Imaging Feature,nodular growth,17890911,N000581
Imaging Feature,number of flow void,30560359,N000582
Imaging Feature,peripheral diffuse infiltration,17890911,N000583
Imaging Feature,presence of intra and peritumoral flow void,30560359,N000584
Imaging Feature,radiological phenotype,37922931,N000585
Imaging Feature,resection potential,31786124,N000586
Imaging Feature,size from 04 up to 95 cm,20123452,N000587
Imaging Feature,size from 05 to 18 cm,18551749,N000588
Imaging Feature,skin discoloration,36254545,N000589
Imaging Feature,slightly enlarged nuclei,17890911,N000590
Imaging Feature,slowly growing indurated dermal plaque or firm nodule attached to the skin,36254545,N000591
Imaging Feature,soft and gelatinou,35673808,N000592
Imaging Feature,solid and cystic mas,35125107,N000593
Imaging Feature,t2w signal intensity,40273759,N000594
Imaging Feature,tumor depth,30421387,N000595
Imaging Feature,tumor diameter,39545983,N000596
Imaging Feature,tumor grade,31786124,N000597
Imaging Feature,tumor location,39545983,N000598
Imaging Feature,tumor ranged from 1 cm to over 10 cm in diameter,16096408,N000599
Imaging Feature,tumor size,31786124,N000600
Imaging Feature,tumor size 8 cm,19828411,N000601
Imaging Feature,tumor volume,15175957,N000602
Imaging Mehtod,18f fdg pet ct,18719909,N000603
Imaging Mehtod,computed tomography,24279301,N000604
Imaging Mehtod,contrast enhanced ct scan,37922931,N000605
Imaging Mehtod,ct,18719909,N000606
Imaging Mehtod,ct based radiomic,37922931,N000607
Imaging Mehtod,f fdg pet alone,18719909,N000608
Imaging Mehtod,fdg pet,33112583,N000609
Imaging Mehtod,magnetic resonance imaging,22134298,N000610
Imaging Mehtod,mri,33112583,N000611
Imaging Mehtod,mri scan,16601376,N000612
Imaging Mehtod,pelvic ultrasonography,35673808,N000613
Imaging Mehtod,pet ct,33112583,N000614
Imaging Mehtod,positron emission tomography,35673808,N000615
Imaging Mehtod,scintigraphy,15968601,N000616
Imaging Mehtod,thoracoabdominal computed tomograph,37879305,N000617
Imaging Mehtod,tumor to background ratio,15968601,N000618
Imaging Mehtod,ultrasound,22134298,N000619
Imaging Mehtod,ultrasound detection,36483242,N000620
Imaging Mehtod,visual inspection of scintigram,15968601,N000621
Marker,alk,26715170,N000622
Marker,alk1,20829680,N000623
Marker,alpha smooth muscle actin,17890911,N000624
Marker,alternative lengthening of telomere alt pathway,15111298,N000625
Marker,apoptotic protease activating factor,34502329,N000626
Marker,aurora kinase a and b mrna expression,29197031,N000627
Marker,bcl 2,21056898,N000628
Marker,bcl2,34502329,N000629
Marker,bcor gene expression,27428733,N000630
Marker,c kit,20829680,N000631
Marker,c met,18753943,N000632
Marker,calsequestrin 2,21412072,N000633
Marker,camta1,28009608,N000634
Marker,cathepsink,26715170,N000635
Marker,cd 31,18225592,N000636
Marker,cd10,26715170,N000637
Marker,cd123,19363438,N000638
Marker,cd163,19363438,N000639
Marker,cd20,19363438,N000640
Marker,cd21,20829680,N000641
Marker,cd3,19363438,N000642
Marker,cd31,20829680,N000643
Marker,cd34,21056898,N000644
Marker,cd34 expression,36254545,N000645
Marker,cd4,19363438,N000646
Marker,cd99,21056898,N000647
Marker,cdk4,33112583,N000648
Marker,cell stiffnes,37700272,N000649
Marker,cell were significant stiffer than the chondrocyte,37700272,N000650
Marker,change in cell cytoskeletal architecture,37700272,N000651
Marker,ck,34502329,N000652
Marker,col1a1 pdgfb fusion gene,17890911,N000653
Marker,collagen iv laminin,20399579,N000654
Marker,complete los of arid1a expression,35125107,N000655
Marker,desmin,20829680,N000656
Marker,egr1,34857011,N000657
Marker,ema,20829680,N000658
Marker,epithelial membrane antigen,17890911,N000659
Marker,ewsr1 and creb3l1 rearrangement,22982887,N000660
Marker,expression of aurora kinase a and b,29197031,N000661
Marker,f actin content wa lowe,37700272,N000662
Marker,factor viii related antigen,17998131,N000663
Marker,fli 1,16096408,N000664
Marker,fosb expression,28009608,N000665
Marker,gria2,26337721,N000666
Marker,h caldesmon,26715170,N000667
Marker,h3k27me3,29773426,N000668
Marker,heparanase,34857011,N000669
Marker,high molecular weight ck,20829680,N000670
Marker,hmb 45,26715170,N000671
Marker,human muscle cofilin2,21412072,N000672
Marker,igg4,19363438,N000673
Marker,ihc expression of stat6,28869107,N000674
Marker,impaired mitochondrial function,39658531,N000675
Marker,ini1,20829680,N000676
Marker,ki 67,21056898,N000677
Marker,ki 67 10%,34502329,N000678
Marker,ki 67 index,36613891,N000679
Marker,les stiff than their corresponding non malignant counterpart,37700272,N000680
Marker,level of mmp 9 monomer and dimer,24378964,N000681
Marker,major histocompatibility complex 1,19363438,N000682
Marker,mdm2,25475695,N000683
Marker,melana,26715170,N000684
Marker,mitf,26715170,N000685
Marker,mitotic count,36613891,N000686
Marker,muc4 expression,22982887,N000687
Marker,myo d1,20829680,N000688
Marker,myogenin,20829680,N000689
Marker,myosin light chain kinase,21412072,N000690
Marker,nab2,26337721,N000691
Marker,neuroendocrine marker,34502329,N000692
Marker,over expression of pdgfbeta,36254545,N000693
Marker,p16,33112583,N000694
Marker,p16 should be used with caution,26715170,N000695
Marker,p53,21056898,N000696
Marker,p53 expression,18753943,N000697
Marker,p53 through it acetylation,34857011,N000698
Marker,p63,20829680,N000699
Marker,pax2,21836481,N000700
Marker,pax8,21836481,N000701
Marker,pcna polyclonal antibodie,18225592,N000702
Marker,pd l1 expression,36438917,N000703
Marker,pdgfr alpha,18753943,N000704
Marker,pdgfr beta,18753943,N000705
Marker,pgp 95 expression in mesenchymal neoplasm,14559978,N000706
Marker,prame,37477762,N000707
Marker,pretreatment level of albumin hemoglobin and neutrophil to lymphocyte ratio,25370967,N000708
Marker,promyelocytic leukemia nuclear body,15111298,N000709
Marker,protein s 100,20399579,N000710
Marker,reduced mitochondrial gene mt rnr2 mtrnr2l12 expression in tme infiltrating cell,39658531,N000711
Marker,s 100 protein,25475695,N000712
Marker,s100,19363438,N000713
Marker,s100 protein,22495377,N000714
Marker,sarcolemmal membrane associated protein,21412072,N000715
Marker,satb2 mrna upregulation,27428733,N000716
Marker,siglec 15 expression,36438917,N000717
Marker,significant upregulation of beta tubulin gene expression,37700272,N000718
Marker,sma,25475695,N000719
Marker,smooth muscle actin,20829680,N000720
Marker,smooth muscle gamma actin,21412072,N000721
Marker,sox10,22495377,N000722
Marker,sox2 protein expression,29773426,N000723
Marker,staining with stat6,30233017,N000724
Marker,stat6,26337721,N000725
Marker,stat6 antibody,26811225,N000726
Marker,suppressive macrophage spp1+ and olr1+,39658531,N000727
Marker,telomerase,15111298,N000728
Marker,telomere length,15111298,N000729
Marker,tert mrna expression,27562490,N000730
Marker,tfe 3,26715170,N000731
Marker,tfe3,28009608,N000732
Marker,tle1,20829680,N000733
Marker,truncated splice variant of aurora kinase b,29197031,N000734
Marker,wide spectrum cytokeratin,20829680,N000735
Marker,wt1,20829680,N000736
Marker,wwtr1 camta1,26811225,N000737
Model Evaluation Method,calculating exces over blis score,36729612,N000738
Model Evaluation Method,calibration curve,39545983,N000739
Model Evaluation Method,confidence interval,31100257,N000740
Model Evaluation Method,hazard ratio,31100257,N000741
Model Evaluation Method,kaplan meier k m curve,39545983,N000742
Model Evaluation Method,log rank test,39545983,N000743
Model Evaluation Method,percentage change in sum of target marker lesion diameter,31160249,N000744
Model Evaluation Method,precision recall p r curve,39545983,N000745
Model Evaluation Method,receiver operator curve,37922931,N000746
Model Evaluation Method,roc,39545983,N000747
Mutation,aberration of the switch sucrose non fermentable,29650362,N000748
Mutation,activating enhancer of zeste homolog 2 ezh2 mutation,29650362,N000749
Mutation,alteration,39563528,N000750
Mutation,bcor internal tandem duplication,27428733,N000751
Mutation,biallelic inactivation mutation of arid1a,35125107,N000752
Mutation,biallelic smarcb1 the gene that encode ini1 alteration,33035459,N000753
Mutation,duplication,17163160,N000754
Mutation,exon 9 insertion duplication ay502 503,17163160,N000755
Mutation,focal copy number gain in chromosome arm 1q 7p 8q 9q and 17q,34464388,N000756
Mutation,focal copy number losse in suz12 smarca2 cdkn2a b and chromosome arm 6p and 9p,34464388,N000757
Mutation,focal nf1 copy number los,34464388,N000758
Mutation,heterozygou los of function variant in the tumor suppressor gene nf1,30006586,N000759
Mutation,hter,34502329,N000760
Mutation,idh wildtype,36729612,N000761
Mutation,idh1 mutant,36729612,N000762
Mutation,idh2 mutant,36729612,N000763
Mutation,in frame deletion,17163160,N000764
Mutation,internal tandem duplication mutation,36264536,N000765
Mutation,kit exon 11 mutation,17163160,N000766
Mutation,los of ini1 expression,33035459,N000767
Mutation,los of the other nf2 allele,17163160,N000768
Mutation,med12 mutation,26715170,N000769
Mutation,mutation of the nf1 gene,34530870,N000770
Mutation,nf1 null,31291965,N000771
Mutation,nonsense or missense mutation in nf2 gene,17163160,N000772
Mutation,pdgfra mutation,17163160,N000773
Mutation,point mutation,17163160,N000774
Mutation,supernumerary ring chromosome,12661001,N000775
Mutation,tert,34502329,N000776
Mutation,tert promoter mutation,27562490,N000777
Mutation,tp53,34502329,N000778
Mutation,truncated splice variant,29197031,N000779
Outcome,1 year 3 year and 5 year overall survival rate for the entire cohort wa 862% 95% confidence interval ci 852% 872% 705% 95% ci 689% 721% and 630% 95% ci 612% 648%,33305494,N000780
Outcome,5 year event free survival and overall survival were 889% 95% ci 840 938 and 962% 932 992 in the low risk group 650% 582 718 and 792% 734 850 in the intermediate risk group and 212% 114 311 and 355% 236 474 in the high risk group,31786124,N000781
Outcome,5 year survival rate 70%,18052409,N000782
Outcome,achieving encouraging result especially with pembrolizumab and doxorubicin at an early stage or ici with antiangiogenic,34925348,N000783
Outcome,activity wa limited,34107450,N000784
Outcome,additional primary malignancie developed,33112583,N000785
Outcome,alive with disease,18551749,N000786
Outcome,alive without disease,20829680,N000787
Outcome,an orr ranging from 20 to 50%,34925348,N000788
Outcome,antiproliferative and pro apoptotic effect,34857011,N000789
Outcome,better o,30421387,N000790
Outcome,cachexia,14670013,N000791
Outcome,complete response,29650362,N000792
Outcome,complete response wa achieved,38014853,N000793
Outcome,dead of disease at 6 month,18580491,N000794
Outcome,death,27562490,N000795
Outcome,delaying disease progression,30477937,N000796
Outcome,detection of distant metastase,18719909,N000797
Outcome,detection of regional lymph node metastase,18719909,N000798
Outcome,did not affect ra activation,31291965,N000799
Outcome,did not alter proliferation,31291965,N000800
Outcome,did not have a significant influence on local recurrence or survival,27834629,N000801
Outcome,did not reduce tumor burden,31331295,N000802
Outcome,did not reduce tumor growth,31331295,N000803
Outcome,did not result in significant anti proliferative or pro apoptotic activity,31331295,N000804
Outcome,did not significantly increase the percentage of polyploid cell,29197031,N000805
Outcome,died,30233017,N000806
Outcome,died of disease,34502329,N000807
Outcome,died of locally aggressive,20829680,N000808
Outcome,died of other cause,20829680,N000809
Outcome,died of tumor related complication,14670013,N000810
Outcome,difficult candidate for surgical treatment,16601376,N000811
Outcome,disappointing response rate of 15%,34925348,N000812
Outcome,disease free,38876200,N000813
Outcome,disease free after treatment,34251596,N000814
Outcome,disease free for one year postoperatively,36254545,N000815
Outcome,disease free survival,28499583,N000816
Outcome,disease specific death,39230901,N000817
Outcome,disease specific mortality,25370967,N000818
Outcome,disease specific survival,30421387,N000819
Outcome,disseminating malignant cell and worsening survival outcome,30447212,N000820
Outcome,distant metastase,29529647,N000821
Outcome,distant metastasi,39417883,N000822
Outcome,distant metastasi free survival,30421387,N000823
Outcome,do not benefit,34925348,N000824
Outcome,dose dependent decrease in the total viable cell number,29197031,N000825
Outcome,dsm,31100257,N000826
Outcome,dsm rate were also higher,31100257,N000827
Outcome,durable objective response,29650362,N000828
Outcome,enhanced antiproliferative and pro apoptotic effect,34857011,N000829
Outcome,esomeprazole modestly decreased pexidartinib exposure,36264536,N000830
Outcome,event free survival,31786124,N000831
Outcome,fatal outcome occurred in 66% of patient wherea 19% were reported alive with or without complication,20399579,N000832
Outcome,five year survival rate wa 643%,17338203,N000833
Outcome,for postoperative radiotherapy median follow up time wa 54 month iqr 32 79 for patient in the postoperative radiotherapy group and 47 month 26 72 for patient in the no radiotherapy group median overall survival wa 89 month 95% ci 79 100 versu 64 month 59 69,27210906,N000834
Outcome,for preoperative radiotherapy median follow up time wa 42 month iqr 27 70 for the preoperative radiotherapy group versu 43 month 25 64 for the no radiotherapy group median overall survival wa 110 month 95% ci 75 not estimable versu 66 month 61 76,27210906,N000835
Outcome,free of disease,34502329,N000836
Outcome,have somewhat promising but still largely uncertain treatment role,38954182,N000837
Outcome,high recurrence rate,31692830,N000838
Outcome,high response rate,34107450,N000839
Outcome,hospitalized,39582122,N000840
Outcome,impaired migration and invasion altered cellular morphology and triggered the accumulation of large intracellular vesicle,34530870,N000841
Outcome,inhibited dna synthesi and viability,31291965,N000842
Outcome,inhibited migration and rock1 phosphorylation,34530870,N000843
Outcome,itraconazole increased pexidartinib exposure,36264536,N000844
Outcome,liver metastasi,25475695,N000845
Outcome,local control,12916461,N000846
Outcome,local recurrence,25370967,N000847
Outcome,local recurrence at 5 year,17890911,N000848
Outcome,local recurrence free survival,30421387,N000849
Outcome,local relapse free survival,19828411,N000850
Outcome,locoregional recurrence,24279301,N000851
Outcome,los of extremity,26905128,N000852
Outcome,low rate of regional metastase,12916461,N000853
Outcome,low sensitivity to cytotoxic chemotherapy,31331701,N000854
Outcome,lymph node metastase,29529647,N000855
Outcome,may improve response,34925348,N000856
Outcome,mean time of recurrence or metastasi i 122 month,20399579,N000857
Outcome,median overall survival wa 190 month,33035459,N000858
Outcome,median progression free survival wa 55 month,33035459,N000859
Outcome,metastase,29529647,N000860
Outcome,metastasi,36613891,N000861
Outcome,metastasi free survival,33112583,N000862
Outcome,metastasized,34502329,N000863
Outcome,metastatic,22134298,N000864
Outcome,mild inhibition of proliferation,31331295,N000865
Outcome,minimal disseminated disease,27591237,N000866
Outcome,multifocality,21045379,N000867
Outcome,multiple recurrence,25475695,N000868
Outcome,narrow surgical margin,36254545,N000869
Outcome,ndsm,31100257,N000870
Outcome,ndsm wa higher,31100257,N000871
Outcome,no death from toxic event,31786124,N000872
Outcome,no death or grade 4 adverse event occurred,31331701,N000873
Outcome,no difference in overall survival benefit,28499583,N000874
Outcome,no evidence of disease,19718788,N000875
Outcome,no further disease progression,36254545,N000876
Outcome,no local or distant recurrence,38876200,N000877
Outcome,no local recurrence,15221986,N000878
Outcome,no objective response,38954182,N000879
Outcome,no postradiotherapy complication,38153106,N000880
Outcome,no regional and or distant metastase,15221986,N000881
Outcome,no significant influence on recurrence or survival,27834629,N000882
Outcome,no treatment related death,28499583,N000883
Outcome,node metastase,15509490,N000884
Outcome,non progressive at 8 week,30477937,N000885
Outcome,objective response according to recist 11,31331701,N000886
Outcome,outcome for patient who present with metastatic disease remain poor,18052409,N000887
Outcome,overall 5 year survival,29529647,N000888
Outcome,overall median survival wa histology specific osteosarcoma 11 month ewing sarcoma 26 month chondrosarcoma 37 month chordoma 50 month and significantly worse in patient with metastasi,21184634,N000889
Outcome,overall survival,31786124,N000890
Outcome,overall survival benefit of 118 month,31331295,N000891
Outcome,partial response,31651363,N000892
Outcome,patient died,27834629,N000893
Outcome,positive therapeutic efficacy,36254545,N000894
Outcome,potentiated the antitumor efficacy against the cme 1 orthotopic s model,34857011,N000895
Outcome,progression,21938461,N000896
Outcome,progressive disease,31651363,N000897
Outcome,promote proliferation and survival but not migration,34530870,N000898
Outcome,pulmonary metastase,18719909,N000899
Outcome,recurred,34502329,N000900
Outcome,recurrence,38153106,N000901
Outcome,recurrence free survival at 25 year,29494352,N000902
Outcome,recurrent,22134298,N000903
Outcome,recurrent disease,15221986,N000904
Outcome,reduced proliferation,31291965,N000905
Outcome,reducing the rate of recurrence,31692830,N000906
Outcome,reducing the viability of chondrosarcoma spheroid and spheroid growth,36729612,N000907
Outcome,regional lymph node metastase,18719909,N000908
Outcome,regression of the tumor at 2 year,17998131,N000909
Outcome,relapse,27562490,N000910
Outcome,repeat surgery,38153106,N000911
Outcome,resistance,36729612,N000912
Outcome,rifampin decreased exposure,36264536,N000913
Outcome,secondary drug resistance,17163160,N000914
Outcome,sensitize chondrosarcoma cell line to chemotherapy temozolomide or radiotherapy,36729612,N000915
Outcome,significant increase in polyploidy,29197031,N000916
Outcome,significant increase starting at 100 nm in the sw 872 cell and 250 nm in the 93t449 cell,29197031,N000917
Outcome,significantly worse recurrence free survival rf p 0001 and overall survival o p 0004,39545983,N000918
Outcome,stable disease,31651363,N000919
Outcome,stage i can be reduced to 4 week without worsening treatment outcome,15175957,N000920
Outcome,substantial activity in asp,31160249,N000921
Outcome,substantially improved prognosi for many cancer type,34107450,N000922
Outcome,sufficient to reduce nf1 associated mpnst viability potentially due inhibition of glycolysi,32948135,N000923
Outcome,survival,29529647,N000924
Outcome,survival rate appear to be higher after surgical treatment and were significantly improved by adjuvant chemotherapy,14670013,N000925
Outcome,survival rate wa better than the case without,20399579,N000926
Outcome,survival rate were 767%,32620510,N000927
Outcome,systemic metastase,39417883,N000928
Outcome,the 3 and 5 year metastasi free survival rate were 86% 95% ci 067 to 100 and 75% 95% ci 049 to 100 respectively,33112583,N000929
Outcome,the ef i identical for patient with stage i and ii n 092 a well a for stage ii n+ and iii 082,15175957,N000930
Outcome,the mean overall survival duration of patient with chordoma chondrosarcoma ewing sarcoma and osteosarcoma wa 6686 95% ci 6406 6966 6353 95% ci 6181 6525 5806 95% ci 5549 6062 and 5491 95% ci 5314 5669 month,33305494,N000931
Outcome,three year cumulative survival rate wa 711%,17338203,N000932
Outcome,treatment failure,31786124,N000933
Outcome,tumor related death,16096408,N000934
Outcome,tumor volume did shrink,15175957,N000935
Outcome,two year cumulative survival rate wa 743%,17338203,N000936
Outcome,ugt inhibition increased pexidartinib exposure,36264536,N000937
Outcome,unresponsive,31160249,N000938
Outcome,usually resistant,16601376,N000939
Outcome,vent free survival ef after 5 year wa 91 %,15175957,N000940
Outcome,well tolerated,33035459,N000941
Pathology Method,fish,27591237,N000942
Pathology Method,fluorescence in situ hybridization,24279301,N000943
Pathology Method,fu,22982887,N000944
Pathology Method,histopathology,37879305,N000945
Pathology Method,immunohistochemical,30233017,N000946
Pathology Method,immunohistochemical analysi,18225592,N000947
Pathology Method,immunohistochemistry,35125107,N000948
Pathology Method,macroscopic examination,24279301,N000949
Pathology Method,p53 immunoreaction,14508393,N000950
Pathology Method,prame immunoreactivity,37477762,N000951
Pathology Method,qpcr,27591237,N000952
Pathology Method,reverse transcription polymerase chain reaction,26337721,N000953
Pathology Method,rt pcr,27591237,N000954
Pathology Method,sensitive ihc,27591237,N000955
Pathology Method,tissue microarray,36613891,N000956
Pathology Method,whole tissue section,36613891,N000957
Prediction Model,clinical model,39545983,N000958
Prediction Model,competing risk model,25370967,N000959
Prediction Model,cox proportional hazard regression,25370967,N000960
Prediction Model,ct based radiomic classification model for the prediction of histological type and grade,37922931,N000961
Prediction Model,exces over blis score,36729612,N000962
Prediction Model,hybrid model modelsupcr sup that amalgamated radiomic and clinical feature,39545983,N000963
Prediction Model,independent predictor of df,36438917,N000964
Prediction Model,multivariable crr model,31100257,N000965
Prediction Model,prognostic biomarker score,25370967,N000966
Prediction Model,radiomic model utilizing multiparametric magnetic resonance imaging mri for the prediction of preoperative risk assessment in gastrointestinal stromal tumor gist,39545983,N000967
Prediction Model,response evaluation criteria in solid tumor,31160249,N000968
Prognosis Category,advanced stage,19828411,N000969
Prognosis Category,adverse outcome,26715170,N000970
Prognosis Category,after preoperative chemotherapy i worse than in any other patient group of intermediate risk,15175957,N000971
Prognosis Category,better prognosi than diffuse anaplasia,15175957,N000972
Prognosis Category,brain metastase,39030374,N000973
Prognosis Category,destructive nature,31692830,N000974
Prognosis Category,disease progression,34857011,N000975
Prognosis Category,dismal prognosi,14670013,N000976
Prognosis Category,distant metastase,29529647,N000977
Prognosis Category,do not shrink during preoperative chemotherapy,15175957,N000978
Prognosis Category,early stage,19828411,N000979
Prognosis Category,five and ten year disease specific mortalitie were underestimated by 31 and 19 percentage,25370967,N000980
Prognosis Category,five and ten year relative mortalitie of 328% and 360%,25370967,N000981
Prognosis Category,five year local recurrence,25370967,N000982
Prognosis Category,fungating mas,26905128,N000983
Prognosis Category,high grade,17338203,N000984
Prognosis Category,high grade and tumor size 17cm,31100257,N000985
Prognosis Category,high local recurrence rate,36254545,N000986
Prognosis Category,high recurrence rate,38153106,N000987
Prognosis Category,high risk,15175957,N000988
Prognosis Category,high risk group,31786124,N000989
Prognosis Category,higher rate of recurrence,31469398,N000990
Prognosis Category,higher risk of lymph node involvement,29529647,N000991
Prognosis Category,highly radio and chemosensitive,18820664,N000992
Prognosis Category,improved overall survival after lymphadenectomy,29529647,N000993
Prognosis Category,intermediate risk,15175957,N000994
Prognosis Category,intermediate risk group,31786124,N000995
Prognosis Category,local recurrence free survival,33112583,N000996
Prognosis Category,locally advanced disease,26905128,N000997
Prognosis Category,locally aggressive,20829680,N000998
Prognosis Category,locally aggressive behavior,36254545,N000999
Prognosis Category,low grade,17338203,N001000
Prognosis Category,low grade and tumor size 17cm,31100257,N001001
Prognosis Category,low mortality,18551749,N001002
Prognosis Category,low risk,15175957,N001003
Prognosis Category,low risk group,31786124,N001004
Prognosis Category,lymph node metastase,29529647,N001005
Prognosis Category,metastasi,26905128,N001006
Prognosis Category,metastasi free survival,33112583,N001007
Prognosis Category,metastatic disease,20829680,N001008
Prognosis Category,overall survival,33112583,N001009
Prognosis Category,poor outcome,21184634,N001010
Prognosis Category,poor prognosi,28988646,N001011
Prognosis Category,poor sarcoma o,36438917,N001012
Prognosis Category,poor survival,33305494,N001013
Prognosis Category,poorer disease free survival,36438917,N001014
Prognosis Category,poorer survival,29529647,N001015
Prognosis Category,rare long term survivor,16096408,N001016
Prognosis Category,rate of recurrence wa 54%,31469398,N001017
Prognosis Category,relatively aggressive clinical outcome,28869107,N001018
Prognosis Category,relatively low risk of metastatic spread,36254545,N001019
Prognosis Category,risk of recurrence,31469398,N001020
Prognosis Category,sepsi,26905128,N001021
Prognosis Category,ulceration,26905128,N001022
Prognosis Category,wound healing complication,35901432,N001023
Reason for drug outcome,activation of a cytoprotective and auto sustaining axi involving erk egr1 and the beta endoglycosidase heparanase,34857011,N001024
Reason for drug outcome,high incidence of metastatic disease,31160249,N001025
Reason for drug outcome,imatinib resistant mutation,17163160,N001026
Reason for drug outcome,lack of efficacy of conventional chemotherapy,31160249,N001027
Reason for drug outcome,poor long term prognosi,31160249,N001028
Reason for drug outcome,proliferative dependency on ezh2 activity,29650362,N001029
Reason for drug outcome,strn3 ntrk3 positive cell were sensitive to larotrectinib in vitro,38014853,N001030
Reason for drug outcome,the combination of saha with sst0001 prevented the upregulation of erk egr1 heparanase induced by the hdaci and promoted caspase dependent cell death,34857011,N001031
Risk Factor,30 year of age,21045379,N001032
Risk Factor,bone and lung metastase,33305494,N001033
Risk Factor,high grade,21045379,N001034
Risk Factor,high grade histology,12916461,N001035
Risk Factor,high lr grade,39230901,N001036
Risk Factor,incomplete resection,14670013,N001037
Risk Factor,larger tumor size,12916461,N001038
Risk Factor,mitotic activity,18551749,N001039
Risk Factor,multifocality,39230901,N001040
Risk Factor,non surgery,33305494,N001041
Risk Factor,older age,27562490,N001042
Risk Factor,positive surgical margin,12916461,N001043
Risk Factor,r1 or r2 margin,39230901,N001044
Risk Factor,regional and distant stag,33305494,N001045
Risk Factor,size,18551749,N001046
Risk Factor,t size 5 cm,21045379,N001047
Risk Factor,t2 stage,33305494,N001048
Risk Factor,tumor in the extremitie,33305494,N001049
Risk Factor,tumoral size,15509490,N001050
Risk Factor,younger age,39230901,N001051
Sarcoma Subtype,alveolar rhabdomyosarcoma,15337565,N001052
Sarcoma Subtype,alveolar soft part sarcoma,31160249,N001053
Sarcoma Subtype,angiosarcoma,22982887,N001054
Sarcoma Subtype,angiosarcoma of the liver,36483242,N001055
Sarcoma Subtype,asp,34925348,N001056
Sarcoma Subtype,atypical lipomatou tumor,33112583,N001057
Sarcoma Subtype,chondrosarcoma,36729612,N001058
Sarcoma Subtype,chordoma,30477937,N001059
Sarcoma Subtype,clear cell sarcoma,17163160,N001060
Sarcoma Subtype,clear cell sarcoma of kidney,27428733,N001061
Sarcoma Subtype,clear cell sarcoma of soft tissue,37477762,N001062
Sarcoma Subtype,clear cell sarcoma of the gastrointestinal tract,29661713,N001063
Sarcoma Subtype,cutaneou angiosarcoma,20123452,N001064
Sarcoma Subtype,dermatofibrosarcoma protuberan,31786124,N001065
Sarcoma Subtype,diffuse type tenosynovial giant cell tumor,38153106,N001066
Sarcoma Subtype,diffuse type tgct,29494352,N001067
Sarcoma Subtype,diffuse type tsgct,32124739,N001068
Sarcoma Subtype,epithelioid hemangioendothelioma,28009608,N001069
Sarcoma Subtype,epithelioid sarcoma,29650362,N001070
Sarcoma Subtype,extraskeletal myxoid chondrosarcoma,28141799,N001071
Sarcoma Subtype,extrathoracic sft,26337721,N001072
Sarcoma Subtype,fibrosarcoma,20829680,N001073
Sarcoma Subtype,gastric gist,17163160,N001074
Sarcoma Subtype,gastrointestinal stromal tumor,30477937,N001075
Sarcoma Subtype,hemangiopericytoma,21056898,N001076
Sarcoma Subtype,high grade undifferentiated spindle cell sarcoma,38178234,N001077
Sarcoma Subtype,high risk soft tissue sarcoma,28499583,N001078
Sarcoma Subtype,infantile fibrosarcoma,17163160,N001079
Sarcoma Subtype,inflammatory myofibroblastic tumor,17163160,N001080
Sarcoma Subtype,leiomyosarcoma,28499583,N001081
Sarcoma Subtype,liposarcoma,28499583,N001082
Sarcoma Subtype,localized type of tsgct,32124739,N001083
Sarcoma Subtype,lower extremity soft tissue sarcoma,35901432,N001084
Sarcoma Subtype,malignant peripheral nerve sheath tumor,28499583,N001085
Sarcoma Subtype,malignant peripheral sheath tumor,38954182,N001086
Sarcoma Subtype,malignant solitary fibrou tumor,34251596,N001087
Sarcoma Subtype,mammary angiosarcoma,15912727,N001088
Sarcoma Subtype,meningeal sft,30233017,N001089
Sarcoma Subtype,meningioma,17163160,N001090
Sarcoma Subtype,metastatic soft tissue sarcoma,27751846,N001091
Sarcoma Subtype,metastatic st,18572972,N001092
Sarcoma Subtype,myxofibrosarcoma,39563528,N001093
Sarcoma Subtype,myxoid dfsp,17890911,N001094
Sarcoma Subtype,non metastatic liposarcoma,30421387,N001095
Sarcoma Subtype,non rhabdomyosarcoma soft tissue sarcoma,31786124,N001096
Sarcoma Subtype,nonmetastatic retroperitoneal sarcoma,31100257,N001097
Sarcoma Subtype,pecoma,26715170,N001098
Sarcoma Subtype,pediatric rm,12916461,N001099
Sarcoma Subtype,pleomorphic liposarcoma,26905128,N001100
Sarcoma Subtype,pleuro pulmonary solitary fibrou tumor,18753943,N001101
Sarcoma Subtype,post mastectomy angiosarcoma,15912727,N001102
Sarcoma Subtype,primary cardiac angiosarcoma,39658531,N001103
Sarcoma Subtype,primary caval leiomyosarcoma,31843478,N001104
Sarcoma Subtype,primary renal synovial sarcoma,17895746,N001105
Sarcoma Subtype,primary synovial sarcoma,15614339,N001106
Sarcoma Subtype,prostatic sft,37879305,N001107
Sarcoma Subtype,renal sft,26337721,N001108
Sarcoma Subtype,retroperitoneal leiomyosarcoma,37922931,N001109
Sarcoma Subtype,retroperitoneal liposarcoma,36438917,N001110
Sarcoma Subtype,retroperitoneal sarcoma,27210906,N001111
Sarcoma Subtype,rhabdomyosarcoma,29529647,N001112
Sarcoma Subtype,round cell liposarcoma,18820664,N001113
Sarcoma Subtype,soft tissue leiomyosarcoma,32075391,N001114
Sarcoma Subtype,soft tissue sarcoma,28499583,N001115
Sarcoma Subtype,solitary fibrou tumor,21056898,N001116
Sarcoma Subtype,sporadic schwannoma,17163160,N001117
Sarcoma Subtype,synovial sarcoma,28499583,N001118
Sarcoma Subtype,tenosynovial giant cell tumo,38153106,N001119
Sarcoma Subtype,tenosynovial giant cell tumor,29494352,N001120
Sarcoma Subtype,unclassified malignant soft tissue sarcoma,31786124,N001121
Sarcoma Subtype,undifferentiated pleiomorphic sarcoma,32075391,N001122
Sarcoma Subtype,undifferentiated pleomorphic sarcoma,28499583,N001123
Sarcoma Subtype,undifferentiated spindle cell sarcoma,35125107,N001124
Sarcoma Subtype,up,34925348,N001125
Sarcoma Subtype,uterine leiomyosarcoma,32075391,N001126
Secondary Tumor,develop malignant tumor,23218951,N001127
Secondary Tumor,distant metastasi,26905128,N001128
Secondary Tumor,malignant fibrou histiocytoma,15337565,N001129
Secondary Tumor,tumor involvement of the inferior vena cava,31843478,N001130
Spread site,anterior compartment,38153106,N001131
Spread site,bone,18551749,N001132
Spread site,dermi,15221986,N001133
Spread site,extraarticular,38153106,N001134
Spread site,liver,18551749,N001135
Spread site,lung,38876200,N001136
Spread site,lymph node,32910462,N001137
Spread site,muscle,15221986,N001138
Spread site,posterior compartment,38153106,N001139
Spread site,regional lymph node,23327728,N001140
Spread site,retroperitoneum,18551749,N001141
Spread site,soft tissue,18551749,N001142
Spread site,subcutaneou tissue,15221986,N001143
Symptom,abdominal pain,24279301,N001144
Symptom,abdominal pressure,35673808,N001145
Symptom,activity limitation,27896676,N001146
Symptom,acute urinary retention,37879305,N001147
Symptom,change in tumor volume,30006586,N001148
Symptom,chest pain,25475695,N001149
Symptom,compression symptom,22002440,N001150
Symptom,constipation,24279301,N001151
Symptom,cough,25475695,N001152
Symptom,dizzines,21938461,N001153
Symptom,dysphagia,25475695,N001154
Symptom,dysuria,35125107,N001155
Symptom,flat plaque,31469398,N001156
Symptom,headache,21938461,N001157
Symptom,hearing los,21938461,N001158
Symptom,high risk for depression anxiety and suicidal ideation,27896676,N001159
Symptom,lesion wa enlarged,25434949,N001160
Symptom,limited rom with a median time before diagnosi of 12 month,29494352,N001161
Symptom,new unexplained neurologic symptom,30006586,N001162
Symptom,obstruction,18580491,N001163
Symptom,obstructive voiding symptom,35125107,N001164
Symptom,orbital mas,21056898,N001165
Symptom,pain,29494352,N001166
Symptom,pain at the site of the tumor,36001000,N001167
Symptom,painful mas,21056898,N001168
Symptom,painles mas,21056898,N001169
Symptom,parotid gland painles mas,22002440,N001170
Symptom,pelvic pain,18580491,N001171
Symptom,physical impairment,27896676,N001172
Symptom,pleural based mas,26811225,N001173
Symptom,postmenopausal abnormal bleeding,17338203,N001174
Symptom,progressive severe pain,30006586,N001175
Symptom,proptosi,21056898,N001176
Symptom,swelling,29494352,N001177
Symptom,unstable walk,21938461,N001178
Symptom,vaginal bleeding,35673808,N001179
Symptom,voiding irritation,18580491,N001180
Synonym for Sarcoma Subtype,a,20123452,N001181
Synonym for Sarcoma Subtype,asl,36483242,N001182
Synonym for Sarcoma Subtype,asp,31160249,N001183
Synonym for Sarcoma Subtype,cc,28141799,N001184
Synonym for Sarcoma Subtype,ccsk,15175957,N001185
Synonym for Sarcoma Subtype,d tgct,38153106,N001186
Synonym for Sarcoma Subtype,ddlp,33112583,N001187
Synonym for Sarcoma Subtype,dfsp,17890911,N001188
Synonym for Sarcoma Subtype,ea,17998131,N001189
Synonym for Sarcoma Subtype,ehe,18580491,N001190
Synonym for Sarcoma Subtype,emc,28141799,N001191
Synonym for Sarcoma Subtype,f,20829680,N001192
Synonym for Sarcoma Subtype,gist,17163160,N001193
Synonym for Sarcoma Subtype,lm,17338203,N001194
Synonym for Sarcoma Subtype,lp,30421387,N001195
Synonym for Sarcoma Subtype,mlm,35673808,N001196
Synonym for Sarcoma Subtype,mlp,28141799,N001197
Synonym for Sarcoma Subtype,mpnst,22495377,N001198
Synonym for Sarcoma Subtype,nmrp,31100257,N001199
Synonym for Sarcoma Subtype,nrst,31786124,N001200
Synonym for Sarcoma Subtype,pca,39658531,N001201
Synonym for Sarcoma Subtype,pigmented villonodular synoviti,38153106,N001202
Synonym for Sarcoma Subtype,rlp,36438917,N001203
Synonym for Sarcoma Subtype,s,20829680,N001204
Synonym for Sarcoma Subtype,sft,36613891,N001205
Synonym for Sarcoma Subtype,soft tissue sarcoma,35901432,N001206
Synonym for Sarcoma Subtype,st,25370967,N001207
Synonym for Sarcoma Subtype,sts,34107450,N001208
Synonym for Sarcoma Subtype,tgct,29494352,N001209
Synonym for Sarcoma Subtype,tsgct,32124739,N001210
Synonym for Sarcoma Subtype,up,34107450,N001211
Treatment,3 brpa treatment,32948135,N001212
Treatment,a backbone of vincristine and dactinomycin with either cyclophosphamide vac or ifosfamide iva,18052409,N001213
Treatment,abdominal sacral,22340347,N001214
Treatment,adjuvant chemotherapy,14670013,N001215
Treatment,adjuvant radiosurgery,21938461,N001216
Treatment,adjuvant radiotherapy,12916461,N001217
Treatment,adjuvant therapy,27834629,N001218
Treatment,adjuvant treatment,21045379,N001219
Treatment,adoptive cellular therapie,34925348,N001220
Treatment,adoptive t cell based immunotherapy,31651363,N001221
Treatment,amputation,26905128,N001222
Treatment,anthracycline with or without ifosfamide,18572972,N001223
Treatment,anti pd l1 therapie,34925348,N001224
Treatment,anti pd1,34107450,N001225
Treatment,anti pd1 + anti cytotoxic t lymphocyte associated protein 4,34107450,N001226
Treatment,anti pd1 + chemo,34107450,N001227
Treatment,anti pd1 + immunomodulator,34107450,N001228
Treatment,anti pd1 + tyrosine kinase inhibitor,34107450,N001229
Treatment,anti pdgfra,31331295,N001230
Treatment,association of ici with chemotherapy,34925348,N001231
Treatment,bilateral salpingo oophorectomy,19828411,N001232
Treatment,bloc resection,17998131,N001233
Treatment,chemoradiotherapy,31786124,N001234
Treatment,chemotherapy,36729612,N001235
Treatment,chemotherapy of combined etoposide and cisplatin,35125107,N001236
Treatment,chemotherapy of doxorubicin and ifosfamide,35125107,N001237
Treatment,classic ra protein,34530870,N001238
Treatment,co administration of pexidartinib,36264536,N001239
Treatment,co treatment with a mek inhibitor trametinib or a heparanase inhibitor sst0001 roneparstat,34857011,N001240
Treatment,combination of doxorubicin and anti pdgfra,31331295,N001241
Treatment,combination with mdm2 antagonist or cdk4 6 inhibitor,34925348,N001242
Treatment,combined multiagent chemotherapy,12916461,N001243
Treatment,complete resection,18753943,N001244
Treatment,complete surgical excision,25475695,N001245
Treatment,conservative excision,31469398,N001246
Treatment,cryoablation,39582122,N001247
Treatment,cyberknife srt,16601376,N001248
Treatment,cytotoxic chemotherapy,31331701,N001249
Treatment,di articulation,26905128,N001250
Treatment,dn r ra expression and rra and rras2 knockdown,34530870,N001251
Treatment,dn r ra inhibition,34530870,N001252
Treatment,enneking appropriate ea resection,27834629,N001253
Treatment,enneking inappropriate ei resection,27834629,N001254
Treatment,erbb4 ablation,31291965,N001255
Treatment,erbb4 knockdown in human mpnst cell,31291965,N001256
Treatment,flap,35901432,N001257
Treatment,free tissue transfer,12916461,N001258
Treatment,gamma knife treatment,16601376,N001259
Treatment,gros total resection,30233017,N001260
Treatment,hdac inhibitor hdaci monotherapie,34857011,N001261
Treatment,histotype tailored chemotherapy,28499583,N001262
Treatment,hysterectomy,30447212,N001263
Treatment,icb monotherapy,34925348,N001264
Treatment,ido blockade,34925348,N001265
Treatment,immune checkpoint inhibitor,34107450,N001266
Treatment,immunotherapy related drug,30646278,N001267
Treatment,inhibition of polyadp ribose polymerase parp,36729612,N001268
Treatment,inhibition of stat3 stat5 and phospholipase cgamma,31291965,N001269
Treatment,intracapsular excision,21045379,N001270
Treatment,intraoperative rt boost,15337565,N001271
Treatment,intraoral resection,22134298,N001272
Treatment,jejunal resection,24279301,N001273
Treatment,limb salvage,35901432,N001274
Treatment,local excision,29529647,N001275
Treatment,local resection,14508393,N001276
Treatment,lymph node excision,29529647,N001277
Treatment,lymphadenectomy,29529647,N001278
Treatment,manipulation under anesthesia,38153106,N001279
Treatment,marginal excision,21045379,N001280
Treatment,marginal resection,15337565,N001281
Treatment,megavoltage radiotherapy,17998131,N001282
Treatment,microwave ablation,39582122,N001283
Treatment,moh micrographic surgery,31469398,N001284
Treatment,moh surgery,36254545,N001285
Treatment,morcellation,30447212,N001286
Treatment,multimodality therapy combining surgery and wide field radiation therapy,12916461,N001287
Treatment,multiportal arthroscopic synovectomy,38153106,N001288
Treatment,neoadjuvant chemoradiation,34251596,N001289
Treatment,neoadjuvant chemoradiotherapy,31786124,N001290
Treatment,neoadjuvant chemotherapy,12916461,N001291
Treatment,neoadjuvant regimen,28499583,N001292
Treatment,open posterior incision,38153106,N001293
Treatment,open resection,29494352,N001294
Treatment,operative procedure,17338203,N001295
Treatment,ovarian tissue cryopreservation,27591237,N001296
Treatment,parp inhibitor,34925348,N001297
Treatment,pelvic lymphadenectomy,19828411,N001298
Treatment,percutaneou ablation,39582122,N001299
Treatment,pik3ca akt inhibition,34925348,N001300
Treatment,post operative chemotherapy,15175957,N001301
Treatment,postoperative adjuvant radiotherapy,38153106,N001302
Treatment,postoperative radiotherapy,27210906,N001303
Treatment,postoperative rt,15337565,N001304
Treatment,preoperative chemotherapy,15175957,N001305
Treatment,preoperative radiation,35901432,N001306
Treatment,preoperative radiotherapy,28499583,N001307
Treatment,radiation,26905128,N001308
Treatment,radiation and chemotherapy,38954182,N001309
Treatment,radiation therapy,16601376,N001310
Treatment,radical resection with adjuvant radiotherapy,20399579,N001311
Treatment,radio and chemo,18820664,N001312
Treatment,radiofrequency ablation,39582122,N001313
Treatment,radiotherapy,25370967,N001314
Treatment,radiotherapy wa performed in addition to excision,23648456,N001315
Treatment,reexcision,17890911,N001316
Treatment,resection,21184634,N001317
Treatment,rock1 inhibition,34530870,N001318
Treatment,saha and sst0001,34857011,N001319
Treatment,single agent doxorubicin,31331295,N001320
Treatment,skin graft,35901432,N001321
Treatment,standard chemotherapy,28499583,N001322
Treatment,stereotactic body radiotherapy,39582122,N001323
Treatment,str,39387992,N001324
Treatment,subtotal resection,20399579,N001325
Treatment,surgery,27210906,N001326
Treatment,surgery alone,31786124,N001327
Treatment,surgery and chemotherapy,18551749,N001328
Treatment,surgery and chemotherapy and or radiation therapy,18551749,N001329
Treatment,surgery with wide excisional margin,38954182,N001330
Treatment,surgical,14670013,N001331
Treatment,surgical excision,38153106,N001332
Treatment,surgical removal,24279301,N001333
Treatment,surgical resection,26970672,N001334
Treatment,surgical treatment,16601376,N001335
Treatment,surgically treated,31100257,N001336
Treatment,talazoparib and radiotherapy,36729612,N001337
Treatment,talazoparib and temozolomide,36729612,N001338
Treatment,targeted oncologic therapy,18572972,N001339
Treatment,targeted therapie,38954182,N001340
Treatment,targeted therapy tyrosine kinase braf or mek inhibitor,30646278,N001341
Treatment,tazemetostat an oral selective ezh2 inhibitor,33035459,N001342
Treatment,tazemetostat monotherapy,29650362,N001343
Treatment,total hysterectomy,19828411,N001344
Treatment,total hysterectomy plu bilateral salpingo oophorectomy,19828411,N001345
Treatment,total hysterectomy with bilateral salpingooophorectomy,17338203,N001346
Treatment,tran abdominal,22340347,N001347
Treatment,tran sacral,22340347,N001348
Treatment,transplantation,27591237,N001349
Treatment,transurethral resection,18580491,N001350
Treatment,treatment aiming at increasing antigenicity,34925348,N001351
Treatment,tur,37879305,N001352
Treatment,tyrosine kinase inhibitor,31160249,N001353
Treatment,wide excision,30421387,N001354
Treatment,wide local excision,36254545,N001355
Treatment,wide surgical excision,12661001,N001356
Treatment,wnk1 inhibition,31291965,N001357
Treatment Response,disease progression wa not noted,16601376,N001358
Treatment Response,impaired migration and invasion but not survival,34530870,N001359
Treatment Response,mas reduction,16601376,N001360
canonical subtype for PEComa,pecoma,26715170,N001361
canonical subtype for alveolar soft part sarcoma,alveolar soft part sarcoma,31160249,N001362
canonical subtype for angiosarcoma,angiosarcoma,22982887,N001363
canonical subtype for chondrosarcoma,chondrosarcoma,36729612,N001364
canonical subtype for clear cell sarcoma,clear cell sarcoma,15175957,N001365
canonical subtype for dermatofibrosarcoma protuberans,dermatofibrosarcoma protuberan,31786124,N001366
canonical subtype for epithelioid hemangioendothelioma,epithelioid hemangioendothelioma,28009608,N001367
canonical subtype for epithelioid sarcoma,epithelioid sarcoma,29650362,N001368
canonical subtype for extraskeletal myxoid chondrosarcoma,extraskeletal myxoid chondrosarcoma,28141799,N001369
canonical subtype for fibrosarcoma,fibrosarcoma,20829680,N001370
canonical subtype for fibrosarcoma,infantile fibrosarcoma,32075391,N001371
canonical subtype for gastrointestinal stromal tumor,gastrointestinal stromal tumor,30477937,N001372
canonical subtype for inflammatory myofibroblastic tumor,inflammatory myofibroblastic tumor,32075391,N001373
canonical subtype for leiomyosarcoma,leiomyosarcoma,28499583,N001374
canonical subtype for liposarcoma,liposarcoma,28499583,N001375
canonical subtype for malignant peripheral nerve sheath tumor,malignant peripheral nerve sheath tumor,28499583,N001376
canonical subtype for malignant peripheral nerve sheath tumor,malignant peripheral sheath tumor,38954182,N001377
canonical subtype for myxofibrosarcoma,myxofibrosarcoma,39563528,N001378
canonical subtype for retroperitoneal sarcoma,retroperitoneal sarcoma,27210906,N001379
canonical subtype for rhabdomyosarcoma,rhabdomyosarcoma,29529647,N001380
canonical subtype for soft tissue sarcoma,soft tissue sarcoma,28499583,N001381
canonical subtype for solitary fibrous tumor,solitary fibrou tumor,21056898,N001382
canonical subtype for synovial sarcoma,clear cell sarcoma,27591237,N001383
canonical subtype for synovial sarcoma,synovial sarcoma,28499583,N001384
canonical subtype for tenosynovial giant cell tumor,tenosynovial giant cell tumor,38153106,N001385
canonical subtype for undifferentiated pleomorphic sarcoma,undifferentiated pleiomorphic sarcoma,32075391,N001386
canonical subtype for undifferentiated pleomorphic sarcoma,undifferentiated pleomorphic sarcoma,28499583,N001387
canonical subtype for undifferentiated spindle cell sarcoma,undifferentiated spindle cell sarcoma,35125107,N001388
